ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+18.68%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$224M
AUM Growth
–
Cap. Flow
+$224M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
57.17%
Holding
159
New
150
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$37.1M |
| 2 |
Keros Therapeutics
KROS
|
$27.4M |
| 3 |
Roivant Sciences
ROIV
|
$14.1M |
| 4 |
Arbutus Biopharma
ABUS
|
$8.67M |
| 5 |
Cytokinetics
CYTK
|
$7.69M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.9% |
| 2 | Technology | 1.4% |
| 3 | Financials | 1.4% |
| 4 | Materials | 1.24% |
| 5 | Consumer Staples | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Royalty Pharma
RPRX
$15.6B
| $37.1M | 13.27% | +1,321,834 | New | +$37.1M |
|
|
2
Keros Therapeutics
KROS
$618M
| $27.4M | 9.78% | +688,316 | New | +$27.4M |
|
|
3
Roivant Sciences
ROIV
$8.15B
| $14.1M | 5.04% | +1,256,591 | New | +$14.1M |
|
|
4
Arbutus Biopharma
ABUS
$711M
| $8.67M | 3.1% | +3,468,824 | New | +$8.67M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $7.69M | 2.75% | +92,082 | New | +$7.69M |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $7.47M | 2.67% | +185,137 | New | +$7.47M |
|
|
MACK
7
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $7.37M | 2.63% | +549,418 | New | +$7.37M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.35M | 2.27% | +108,000 | New | +$6.35M |
|
9
Merck
MRK
$210B
| $5.89M | 2.1% | +54,000 | New | +$5.89M |
|
10
Ascendis Pharma
ASND
$11.8B
| $5.78M | 2.07% | +45,884 | New | +$5.78M |
|
11
Immunovant
IMVT
$2.56B
| $5.65M | 2.02% | +134,125 | New | +$5.65M |
|
12
Viking Therapeutics
VKTX
$3.04B
| $4.73M | 1.69% | +254,151 | New | +$4.73M |
|
|
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.69M | 1.68% | +110,700 | New | +$4.69M |
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $4.61M | 1.65% | +200,859 | New | +$4.61M |
|
15
Fulcrum Therapeutics
FULC
$351M
| $4.3M | 1.54% | +637,405 | New | +$4.3M |
|
16
Cellectar Biosciences
CLRB
$15.5M
| $3.82M | 1.36% | +1,378,082 | New | +$3.82M |
|
|
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $3.17M | 1.13% | +10,000 | New | +$3.17M |
|
18
OmniAb
OABI
$230M
| $2.95M | 1.05% | +478,171 | New | +$2.95M |
|
|
AYX
19
DELISTED
Alteryx, Inc.
AYX
| $2.93M | 1.05% | +62,038 | New | +$2.93M |
|
20
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $2.92M | 1.05% | +32,000 | New | +$2.92M |
|
21
WisdomTree Floating Rate Treasury Fund
USFR
$18.8B
| $2.81M | 1.01% | +56,000 | New | +$2.81M |
|
22
Corteva
CTVA
$50.4B
| $2.78M | 0.99% | +58,000 | New | +$2.78M |
|
23
iShares Short Treasury Bond ETF
SHV
$20.8B
| $2.7M | 0.96% | +24,500 | New | +$2.7M |
|
24
Vanguard Ultra-Short Bond ETF
VUSB
$5.48B
| $2.48M | 0.89% | +50,206 | New | +$2.48M |
|
25
SPDR SSGA Ultra Short Term Bond ETF
ULST
$616M
| $2.47M | 0.88% | +61,264 | New | +$2.47M |
|